TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07073950: A Randomised, Double-blind, Multi-centre, Placebo-controlled, Crossover Study to Assess the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler on Cardiac and Lung Function in Participants With C

Sponsor: AstraZeneca · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 56 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,258,880

Rescue Site Savings

+$3,479,360

Unlock Full NCT07073950 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07073950 Rescue Dossier →